Testing strategy for laboratory monitoring of Hemophilia A patients treated with Emicizumab

被引：0
|
作者：
Pikta, M. [1 ]
Saks, K. [4 ]
Ross, M. [3 ]
Banys, V. [2 ]
机构：
[1] Tallinn Univ Technol, Dept Hlth Technol, Dept Lab Med, North Estonia Med Ctr, Tallinn, Estonia
[2] Vilnius Univ, Inst Biomed Sci, Dept Physiol Biochem Microbiol & Lab Med, Fac Med, Vilnius, Lithuania
[3] North Estonia Med Ctr, Dept Hematol, Tallinn, Estonia
[4] Tallinn Childrens Hosp, Dept Hematol, Tallinn, Estonia
来源：
CLINICA CHIMICA ACTA | 2022年 / 530卷
关键词：
D O I：
10.1016/j.cca.2022.04.750
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
T262
引用
收藏
页码：S186 / S186
页数：1
相关论文
共 50 条
  • [31] Problems in laboratory testing: hemophilia and beyond
    Favaloro, E. J.
    Lippi, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (05) : 1119 - 1120
  • [32] Problems and Solutions in Laboratory Testing for Hemophilia
    Favaloro, Emmanuel J.
    Meijer, Piet
    Jennings, Ian
    Sioufi, John
    Bonar, Roslyn A.
    Kitchen, Dianne P.
    Kershaw, Geoffrey
    Lippi, Giuseppe
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (07): : 816 - 833
  • [33] Efficacy and safety of prophylaxis with emicizumab in hemophilia A: A study of 13 patients
    Gomez, M. Angeles Ocana
    Machin, Alejandro Ferrer
    Cabrera, Martin Vera
    Tosco, Karen Ilenia Alvarez
    De Paz, Mario Rios
    Garcia, Dolores De Dios
    MEDICINA CLINICA, 2024, 162 (03): : 134 - 137
  • [34] Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A
    Josset, Laurie
    Leuci, Alexandre
    Janbain, Maissaa
    De-Wreede, Anaelle
    Desage, Stephanie
    Lienhart, Anne
    Bin, Valerie
    Lebert, Dorothee
    Delavenne, Xavier
    Dargaud, Yesim
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 22 (07) : 1857 - 1866
  • [35] Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
    Mahlangu, J.
    Oldenburg, J.
    Paz-Priel, I.
    Negrier, C.
    Niggli, M.
    Mancuso, M. E.
    Schmitt, C.
    Jimenez-Yuste, V.
    Kempton, C.
    Dhalluin, C.
    Callaghan, M. U.
    Bujan, W.
    Shima, M.
    Adamkewicz, J. I.
    Asikanius, E.
    Levy, G. G.
    Kruse-Jarres, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09): : 811 - 822
  • [36] Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A
    Diaz-Ricart, M.
    Isola, I. M.
    Escolar, G.
    DRUGS OF TODAY, 2018, 54 (10) : 591 - 600
  • [37] A SURVEY STUDY OF HEMATOLOGISTS IN THE UNITED STATES TO UNDERSTAND DISEASE MANAGEMENT OF PATIENTS WITH HEMOPHILIA A (PWHA) TREATED WITH EMICIZUMAB (EMI)
    Owens, W. E.
    Patel, A. M.
    Poulos, K.
    Bernard, J.
    Powers, J.
    Ko, R. H.
    HAEMOPHILIA, 2020, 26 : 131 - 132
  • [38] COMBINATION OF EMICIZUMAB WITH SIM OCT OCOG ALFA FOR PROPHYLAXIS IN PREVIOUSLY UNTREATED/MINIMALLY TREATED HEMOPHILIA A PATIENTS, AND FOR MANAGING INHIBITOR PATIENTS
    Sidonio, R.
    Meeks, S. L.
    Shapiro, A.
    Manco-Johnson, M.
    Callaghan, M.
    HAEMATOLOGICA, 2019, 104 : 16 - 17
  • [39] CARRIER TESTING STRATEGY IN HEMOPHILIA-A
    JANCO, RL
    PHILLIPS, JA
    ORLANDO, P
    DAVIES, KE
    OLD, J
    ANTONARAKIS, SE
    LANCET, 1986, 1 (8473): : 148 - 149
  • [40] COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS
    Olasupo, O.
    Matino, D.
    Iorio, A.
    Blackhouse, G.
    Xie, F.
    Tarride, J. E.
    VALUE IN HEALTH, 2022, 25 (07) : S428 - S428
12345